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Summary
The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk 
factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal 
tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell 
lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large 
B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary 
CBCLs. Classically, the cutaneous manifestation of this lymphoma is a red or violaceous tumors arising on a leg. To date, 
despite the large body of evidence suggesting that diabetes is strongly associated with an increased risk of some cancers, 
very little information is available regarding a possible association between type 2 diabetes and primary cutaneous 
diffuse large B-cell lymphoma. In this report, we will present the case of a white adult patient with type 2 diabetes with 
chronic leg ulcers complicated by a primary cutaneous diffuse large B-cell lymphoma.
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Learning points:
•	 Diabetes mellitus is increasing worldwide as well as the incidence of many cancers.
•	 Diabetes mellitus is a powerful risk factor for some cancers (including lymphomas) and is strongly associated with 
adverse cancer outcomes.
•	 Seen that diabetes is strongly associated with an increased risk of cancers (including cutaneous lymphomas), 
clinicians should always keep in mind this complication in elderly patients with type 2 diabetes, even in a chronic 
leg ulcer with hypertrophy of the wound edge, which is hard to heal and does not have the typical characteristics 
of a diabetic or vascular ulcer. In these cases, a biopsy should be performed to rule out a neoplasm.
•	 Early diagnosis and correct management of cancer in a patient with type 2 diabetes are crucial to improve clinical 
outcomes.
Background
In 2014, the total prevalence of type 2 diabetes (T2DM) 
was calculated to be 9% of the adult population (roughly 
415 million individuals) (1). However, it is estimated that 
the total prevalence of diabetes mellitus will increase to 
nearly 600 million in 2035 and that approximately 80% 
of these individuals will live in developing countries (1). 
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In addition to the excess risk of vascular and infectious 
disease, recent data strongly suggest that patients with 
T2DM had a two-fold increased risk of dying from cancer, 
including lymphomas, compared to those without 
diabetes (2, 3).
The skin is the second most frequent extranodal 
site associated with non-Hodgkin lymphomas, after the 
gastrointestinal tract (4). Classically, the identification of 
a primary cutaneous lymphoma necessitates that there is 
no extracutaneous disease involved at the moment of the 
diagnosis (4). Although the cutaneous T-cell lymphomas 
(CTCLs) are the more common subtype, the cutaneous 
B-cell lymphomas (CBCLs) range from 25% to 30% of 
all primary cutaneous lymphomas (5, 6, 7). To note, 
the primary cutaneous diffuse large B-cell lymphoma 
(PCDLBCL), leg type, is a rare and aggressive lymphoma, 
which represents approximately 4% of all cutaneous 
lymphomas and 20% of all primary CBCLs (5, 6, 7). 
PCDLBCL often affects elderly individuals and females 
seem to be more affected than male (5, 6, 7). Traditionally, 
the cutaneous manifestation of this lymphoma is a red 
or violaceous tumors that becomes apparent on a leg (4). 
At present, although there are many data regarding the 
impact of diabetes on the risk of some cancers, very little 
information is available on a possible association between 
T2DM and PCDLBCL. In this report, we will present the 
case of a white adult patient with T2DM with chronic leg 
ulcers complicated by a PCDLBCL.
Case presentation
An 81-year-old white male patient with T2DM was admitted 
to our department for the worsening of the two ulcerative 
left lower limb injuries. The diagnosis of T2DM was made 
approximately 20 years ago and a treatment with insulin 
(lispro plus glargine) was initiated in 2009 with a moderate 
glycemic compensation. In addition to T2DM, his medical 
history included: hypertension, obesity, chronic kidney 
disease (stage IIIa), peripheral arteriopathy, ischemic heart 
disease and a newly-diagnosed hepatic nodule compatible 
with a well-differentiated hepatocellular carcinoma. To 
note, the patients was not a smoker. The ulcerative left 
lower limb injuries appeared three months ago. They had 
been treated with a conservative approach by dressings 
with topical antiseptic and oral antibiotic therapy with 
ciprofloxacin plus amoxicillin-clavulanate, according 
to Klebsiella pneumoniae multi-drug resistant and 
Acinetobacter baumanii isolated by biopsy performed in 
an ambulatory setting. Notably and interestingly, in the 
last month, there has been an increase of the hypertrophy 
of the wound edge. On admission, the patient was afebrile, 
but had pain in the left leg. The larger leg chronic ulcer 
had a size of 84 × 50 mm, while the smaller one had a size 
of 36 × 16 mm. Both ulcers appeared infected, malodorous, 
very erythematous with net and hypertrophic margins 
(Fig.  1). Another similar lesion was found in the dorsal 
part of the left ankle. Given the previous microbiological 
examination, the patient was placed in contact isolation.
Investigation
At admission, blood tests revealed: white blood cells 
(WBC) 5.1 × 109/L (normal range: 4.3–10), hemoglobin 
104 g/L (normal range: 135–170), platelets 125 × 100 000/
mm3 (normal range: 150–450), fasting plasma glucose 
6.4 mmol/L (normal range: 3.5–5.5), A1c 42 mmol/mol 
(normal range: <36), alanine aminotransferase (ALT) 42 U/L 
(normal range: 6–50), gamma-glutamyl transpeptidase 
(GGT) 107 U/L (normal range: 4–60), creatinine 70 µmol/L 
(normal range: 53–115), C-reactive protein (CRP) 17 mg/L 
(normal range <5) and procalcitonin (PCT) 0.04 ng/mL 
(normal range <0.05), carcinoembryonic antigen (CEA) 
1.9 µg/L (normal range <4.0), carbohydrate antigen (CA) 
19–94 KU/L (normal range <35) and alpha-feto protein 
(AFP) <1 KU/L (normal range <10). We performed a new 
biopsy of the soft tissue at the level of the larger leg ulcer, 
that confirmed the presence of Klebsiella pneumoniae and 
Acinetobacter baumannii, but also revealed the presence 
of Staphylococcus aureus methicillin-resistant. After 
the infectious disease counseling, we started a systemic 
antibiotic therapy with carbapenem plus tigecycline at 
high dosages. The radiograph of the left leg excluded the 
presence of underlying osteomyelitis, but the radiologist 
reported the presence of some coarse nodules in the lower 
third of the left leg. Regular medications in combination 
with targeted systemic antibiotic therapy contributed 
Figure 1
Clinical aspect of the larger leg ulcer at presentation. The net and 
hypertrophic margins of the injury are indicated by arrows.
PROOF ONLY
A Mantovani and others ID: 17-0032; May 2017
DOI: 10.1530/EDM-17-0032
Primary cutaneous B-cell 
lymphoma and T2DM
http://www.edmcasereports.com 3
to the reduction of inflammatory markers (CRP 5 mg/L) 
and the improvement of the inflammatory component 
of the ulcers. However, the unusual appearance of the 
ulcers as well as the detection of coarse nodulation on 
radiography imposed the execution of an incisional 
biopsy with subsequent histological examination that 
revealed an infiltrate of monomorphic large cells in the 
dermis with prominent nucleoli and frequent mitoses. 
The immunohistochemical analysis showed a diffuse 
expression of CD20, BCL-2, BCL-6 and MUM-1 as well 
as a high proliferative index (Ki67 >90%) (Fig.  2, Panel 
A, B, C and D). The final diagnosis was a PCDLBCL, ‘leg 
type’, according to World Health Organization (WHO) 
Lymphoma Classification (7). Subsequently, we performed 
a total-body CT that confirmed the presence of the hepatic 
nodule and excluded other extracutaneous disease.
Treatment, outcome and follow-up
The clinical case was extensively discussed with 
hematologist and radiotherapist, who suggested only 
a localized electron beam radiotherapy. The cycles 
of radiotherapy still in progress have allowed an 
improvement of the lesion. In addition, the antibiotic 
therapy was continued for other 3 weeks. The subsequent 
microbiological tests were negative. After discharge, a 
positron emission tomography (PET) scan was performed 
showing the presence of numerous hypermetabolic 
lymph nodes in the left groin and at the level of the 
ipsilateral external and common iliac artery. In addition, 
the spleen was hypermetabolic and increased in volume. 
Collectively, these findings strongly suggest a progression 
of disease.
Discussion
The incidences of T2DM and cancers are rapidly increasing 
worldwide (1). In 2012, the number of deaths ascribed 
to cancer was estimated to have exceeded 8 million and 
the incidence rates of some cancers, including breast 
cancer, lung cancer, prostate cancer and non-Hodgkin 
lymphomas, are expected to raise in the future (2). 
Over the last 50  years, mounting evidence has clearly 
documented that there is a strong and independent 
association between diabetes and some cancers, including 
lymphomas (2). For example, in a community-based 
cohort study involving 820 900 individuals, Seshasai et al. 
have reported that diabetes was strongly associated 
with substantial premature death from several cancers, 
independent of many important risk factors and potential 
confounders (8). More recently, in a small observational 
study including 144 patients with cutaneous T-cell 
lymphomas at Helsinki University Central Hospital, 
Väkevä  et  al. have documented that the prevalence of 
T2DM was significantly increased among patients with 
cutaneous T-cell lymphomas (without a relationship 
with obesity) compared with an age-standardized control 
population (9).
As known, after gastrointestinal tract, the skin is the 
second most frequent extranodal site implied by non-
Hodgkin lymphomas (4). Generally, the cutaneous T-cell 
lymphomas are more common than cutaneous B-cell 
lymphomas, which are a quarter of all primary cuta-
neous lymphomas (5, 6, 7). Notably, the PCDLBCL, also 
named ‘leg type’, is an infrequent lymphoma with a poor 
prognosis (5, 6, 7).
Our patient was an 81-year-old male with T2DM 
complicated by chronic and infected leg ulcerations. 
Importantly, the features of leg ulcers were somewhat 
atypical for a diabetic or vascular injury, in as much as 
they were red and characterized by net and hypertrophic 
margins. Given the unusual features of these lesions, 
the chronicity as well as the persistence of infection 
(despite a targeted oral antibiotic therapy), we performed 
a histological investigation. To our surprise, we found 
a PCDLBCL, ‘leg type’, with a high cell proliferation 
(Fig. 2, Panel A, B, C and D). The total-body CT excluded 
the presence of other extracutaneous disease, with the 
exception of the hepatic nodule, which was already 
known and was periodically checked by imaging. Thus, a 
diagnosis of PCDLBCL was formulated. Subsequently, the 
PET scan showed a progression of disease, confirming the 
poor outcome.
Figure 2
Incisional biopsy of the leg ulcer. Panel A: Histological findings of a 
primary cutaneous diffuse large B-cell lymphoma, leg type. Panel B: 
Immunohistochemical analysis of Ki67 shows a high cell proliferation 
(>90%). Panel C: Immunohistochemical analysis of CD20. Panel D: 
Immunohistochemical analysis of Bcl-2.
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To date, the physiopathology of PCDLBCL is not 
completely understood. The cause seems to be multifactorial 
involving chronic antigen stimulation, such as viral and 
bacterial infections (4, 5, 6, 7). Obesity and T2DM are 
strongly associated with insulin resistance and also with 
a chronic inflammatory state, promoting the release into 
bloodstream of several molecules, such as interleukin-1 (IL-
1), IL-6 and tumor necrosis factor-alpha (TNF-α) (2). When 
insulin resistance develops, insulin concentrations raise 
in the blood, resulting in an overproduction of insulin-
like growth factor 1 (IGF-1), which can stimulate cellular 
proliferation, and also inhibit apoptosis (2). There is now 
convincing evidence to suggest that all these diabetes-
related mediators can concur to the development of certain 
cancers by promoting cellular growth and proliferation, 
inhibition of cellular apoptosis, angiogenesis and DNA 
damage (2). Interestingly, emerging experimental studies 
also suggest that, compared with those without T2DM, 
patients with T2DM have a higher level of genomic 
instability as well as several epigenetic alterations that may 
play a role in the development of cancer (2). Furthermore, 
our patient has been treated with insulin for a long time. 
It is important to remember that several glucose-lowering 
agents (including insulin) are associated with cancer risk 
(2). In particular, some clinical studies published in 2009 
suggested the existence of a significant association between 
the use of glargine and the increased risk of cancer (2). A 
potential biological mechanism of this relationship was 
provided by experimental studies suggesting that glargine 
may have mitogenic property and increase the activity of 
the IGF-1 receptor (2). However, these studies have been 
largely criticized for some methodological limitations, and 
these results have not been confirmed in other subsequent 
studies (2, 10).
In conclusion, our case report is clinically relevant 
as it highlights the finding of a PCDLBCL in a chronic 
leg ulcer in a patient with T2DM. Seen that diabetes 
is strongly associated with an increased risk of some 
cancers (including lymphomas), clinicians should always 
consider this event in elderly patients with T2DM, even in 
a chronic ulcer with hypertrophic margins, which is hard 
to heal and does not have the typical characteristics of a 
diabetic or vascular ulcer. In these cases, a biopsy should be 
performed to rule out a neoplasm. Histological differential 
diagnosis includes epidermal cancers, melanoma, Kaposi’s 
sarcoma and cutaneous B-cell and T-cell lymphomas. 
Finally, the early diagnosis and management of cancer are 
crucial to improve clinical outcomes.
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